organization · Reporting owner

Portfolio Services Ltd.

Disclosed activity across 4 companies

Tapewire entity: 145379
SEC CIK: 0001488856

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

No relationships currently tracked through insider filings.

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

No balances currently tracked through insider filings.

Past disclosures · reporting ended (4)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Avid Bioservices, Inc.

Report date September 11, 2017 · Filed September 29, 2017

Jointly reported with Eastern Capital LTD, DART KENNETH BRYAN

Section 16 reporting ended · disclosed 2017-09-29. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	3,777,183	Reported balance Holding disclosure · report date 2017-09-11 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 3,777,183
10.5% Series E Convertible Preferred StockSEC Table II · derivative / convertible security	Direct	440,000	Reported balance Holding disclosure · report date 2017-09-11 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance 440,000 F1: Each share of Series E Preferred Stock is convertible at any time at the option of the Reporting Persons into the number of whole shares of the Issuer's common stock which is equal to $25.00 per share, plus accrued and unpaid dividends, divided by a conversion price of $21.00. In the event of a change of control (as further described in the certificate of designation of rights and preferences for the Series E Preferred Stock, or Certificate of Designations, filed as Exhibit 3.11 to the Company's Form 8-A filed with the US Securities Exchange Commission on February 12, 2014), the holders of Series E Preferred Stock will be limited to a maximum number of shares of the Issuer's common stock or other applicable consideration equal to 29 (the "Share Cap") multiplied by the number of shares of Series E Preferred Stock converted. F2: The Series E Preferred Stock has no stated maturity, is not subject to any sinking fund or mandatory redemption, and will remain outstanding indefinitely unless the Issuer repurchases, redeems or converts it into the Issuer's common stock in connection with a Change of Control or a Market Trigger (as defined in the Issuer's Prospectus as filed with the US Securities Exchange Commission on February 12, 2014), or unless the Reporting Persons choose to convert the Series E Preferred Stock into the Issuer's common stock.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Series E Preferred Stock is convertible at any time at the option of the Reporting Persons into the number of whole shares of the Issuer's common stock which is equal to $25.00 per share, plus accrued and unpaid dividends, divided by a conversion price of $21.00. In the event of a change of control (as further described in the certificate of designation of rights and preferences for the Series E Preferred Stock, or Certificate of Designations, filed as Exhibit 3.11 to the Company's Form 8-A filed with the US Securities Exchange Commission on February 12, 2014), the holders of Series E Preferred Stock will be limited to a maximum number of shares of the Issuer's common stock or other applicable consideration equal to 29 (the "Share Cap") multiplied by the number of shares of Series E Preferred Stock converted.

F2: The Series E Preferred Stock has no stated maturity, is not subject to any sinking fund or mandatory redemption, and will remain outstanding indefinitely unless the Issuer repurchases, redeems or converts it into the Issuer's common stock in connection with a Change of Control or a Market Trigger (as defined in the Issuer's Prospectus as filed with the US Securities Exchange Commission on February 12, 2014), or unless the Reporting Persons choose to convert the Series E Preferred Stock into the Issuer's common stock.

Bio Green Med Solution, Inc.

Report date April 24, 2020 · Filed May 05, 2020

Jointly reported with Eastern Capital LTD, DART KENNETH BRYAN

Section 16 reporting ended · disclosed 2020-05-05. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	65,863	Reported balance Holding disclosure · report date 2020-04-24 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 65,863 F1: On July 19, 2017 Eastern Capital Limited acquired 850,000 Class A Units. Each Class A Unit consists of one share of the Issuer's common stock and a warrant to purchase one share of the Issuer's common stock which is exercisable as of July 21, 2017 with an exercise price of $2.00 per share and which expires on July 22, 2024. The current holdings reflect adjustments for reverse stock split of the Issuer's common stock and warrant that was effected on April 14, 2020.
WarrantSEC Table II · derivative / convertible security	Direct	1	Reported balance Holding disclosure · report date 2020-04-24 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance 1 F1: On July 19, 2017 Eastern Capital Limited acquired 850,000 Class A Units. Each Class A Unit consists of one share of the Issuer's common stock and a warrant to purchase one share of the Issuer's common stock which is exercisable as of July 21, 2017 with an exercise price of $2.00 per share and which expires on July 22, 2024. The current holdings reflect adjustments for reverse stock split of the Issuer's common stock and warrant that was effected on April 14, 2020.

Filing footnotes · ownership attribution and instrument terms

F1: On July 19, 2017 Eastern Capital Limited acquired 850,000 Class A Units. Each Class A Unit consists of one share of the Issuer's common stock and a warrant to purchase one share of the Issuer's common stock which is exercisable as of July 21, 2017 with an exercise price of $2.00 per share and which expires on July 22, 2024. The current holdings reflect adjustments for reverse stock split of the Issuer's common stock and warrant that was effected on April 14, 2020.

Marker Therapeutics, Inc.

Report date November 09, 2020 · Filed November 13, 2020

Jointly reported with Eastern Capital LTD, DART KENNETH BRYAN

Section 16 reporting ended · disclosed 2020-11-13. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	4,050,001	Reported balance Holding disclosure · report date 2020-11-09 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 4,050,001
Series F-1 WarrantSEC Table II · derivative / convertible security · Expires 2021-08-11	Direct	1	Reported balance Holding disclosure · report date 2020-11-09 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance 1 F1: Series F-1 Warrant is exercisable upon the date of issuance with an exercise price of $7.20 per share and expires on the five year anniversary of the date of issuance

Filing footnotes · ownership attribution and instrument terms

F1: Series F-1 Warrant is exercisable upon the date of issuance with an exercise price of $7.20 per share and expires on the five year anniversary of the date of issuance

iBio, Inc.

Report date August 07, 2020 · Filed August 11, 2020

Jointly reported with Eastern Capital LTD, DART KENNETH BRYAN

Section 16 reporting ended · disclosed 2020-08-11. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	33,114,597	Reported balance After 2020-08-07 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2020-08-07 · Conversion · Acquired 28,925,000 · Balance 33,114,597 F1: On August 6, 2020 Eastern Capital Limited provided notice to the Issuer with effect on August 7, 2020 to convert the shares of Series B Preferred Stock ("Preferred Shares") into shares of Common Stock. The Preferred Shares were convertible into Shares at the option of the holder, at any time, at a conversion price equal to $0.20 per share. As a result, the Preferred Shares converted into 28,925,000 shares of Common Stock.
Common StockSEC Table I · non-derivative	Direct	31,758,993	Reported balance After 2020-08-07 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2020-08-07 · Sale · Disposed 1,355,604 · Balance 31,758,993 F2: The Price reported in Column 4 is a weighted average price. This transaction was executed in multiple trades at prices ranging from $3.62 to $4.08. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff, the Issuer or a security holder of the Issuer upon request.
Common StockSEC Table I · non-derivative	Direct	24,494,129	Reported balance After 2020-08-10 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2020-08-10 · Sale · Disposed 7,264,864 · Balance 24,494,129 F3: The Price reported in Column 4 is a weighted average price. This transaction was executed in multiple trades at prices ranging from $3.65 to $4.53. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff, the Issuer or a security holder of the Issuer upon request.
Common StockSEC Table I · non-derivative	Direct	8,629,693	Reported balance After 2020-08-11 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2020-08-11 · Sale · Disposed 15,864,436 · Balance 8,629,693 F4: The Price reported in Column 4 is a weighted average price. This transaction was executed in multiple trades at prices ranging from $2.69 to $3.69. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff, the Issuer or a security holder of the Issuer upon request
Series B Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.20	Direct	0	Reported balance After 2020-08-07 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-08-07 · Conversion · Disposed 5,785 · Balance 0 F1: On August 6, 2020 Eastern Capital Limited provided notice to the Issuer with effect on August 7, 2020 to convert the shares of Series B Preferred Stock ("Preferred Shares") into shares of Common Stock. The Preferred Shares were convertible into Shares at the option of the holder, at any time, at a conversion price equal to $0.20 per share. As a result, the Preferred Shares converted into 28,925,000 shares of Common Stock.

Filing footnotes · ownership attribution and instrument terms

F1: On August 6, 2020 Eastern Capital Limited provided notice to the Issuer with effect on August 7, 2020 to convert the shares of Series B Preferred Stock ("Preferred Shares") into shares of Common Stock. The Preferred Shares were convertible into Shares at the option of the holder, at any time, at a conversion price equal to $0.20 per share. As a result, the Preferred Shares converted into 28,925,000 shares of Common Stock.

F2: The Price reported in Column 4 is a weighted average price. This transaction was executed in multiple trades at prices ranging from $3.62 to $4.08. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff, the Issuer or a security holder of the Issuer upon request.

F3: The Price reported in Column 4 is a weighted average price. This transaction was executed in multiple trades at prices ranging from $3.65 to $4.53. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff, the Issuer or a security holder of the Issuer upon request.

F4: The Price reported in Column 4 is a weighted average price. This transaction was executed in multiple trades at prices ranging from $2.69 to $3.69. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff, the Issuer or a security holder of the Issuer upon request

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 11, 2020 Filed Aug 11, 2020 17:08 UTC	iBio, Inc. IBIO · Entity 6906	SaleCommon Stock	15,864,436	$2.92	$46,330,498.89	Disclosure SEC source: 0001408408-20-000047 · ownership.xml · nonDerivative · entry 4 Eastern Capital LTD · CIK 0001408408 · 10% owner Portfolio Services Ltd. · CIK 0001488856 · 10% owner DART KENNETH BRYAN · CIK 0001331271 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,629,693 F4 · security: The Price reported in Column 4 is a weighted average price. This transaction was executed in multiple trades at prices ranging from $2.69 to $3.69. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff, the Issuer or a security holder of the Issuer upon request F4 · price: The Price reported in Column 4 is a weighted average price. This transaction was executed in multiple trades at prices ranging from $2.69 to $3.69. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff, the Issuer or a security holder of the Issuer upon request Read SEC document
August 10, 2020 Filed Aug 11, 2020 17:08 UTC	iBio, Inc. IBIO · Entity 6906	SaleCommon Stock	7,264,864	$3.91	$28,429,592.29	Disclosure SEC source: 0001408408-20-000047 · ownership.xml · nonDerivative · entry 3 Eastern Capital LTD · CIK 0001408408 · 10% owner Portfolio Services Ltd. · CIK 0001488856 · 10% owner DART KENNETH BRYAN · CIK 0001331271 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,494,129 F3 · security: The Price reported in Column 4 is a weighted average price. This transaction was executed in multiple trades at prices ranging from $3.65 to $4.53. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff, the Issuer or a security holder of the Issuer upon request. F3 · price: The Price reported in Column 4 is a weighted average price. This transaction was executed in multiple trades at prices ranging from $3.65 to $4.53. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff, the Issuer or a security holder of the Issuer upon request. Read SEC document
August 07, 2020 Filed Aug 11, 2020 17:08 UTC	iBio, Inc. IBIO · Entity 6906	ConversionSeries B Preferred Stock · Derivative	5,785	Not disclosed Strike: $0.20	Not disclosed	Disclosure SEC source: 0001408408-20-000047 · ownership.xml · derivative · entry 5 Eastern Capital LTD · CIK 0001408408 · 10% owner Portfolio Services Ltd. · CIK 0001488856 · 10% owner DART KENNETH BRYAN · CIK 0001331271 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,925,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: On August 6, 2020 Eastern Capital Limited provided notice to the Issuer with effect on August 7, 2020 to convert the shares of Series B Preferred Stock ("Preferred Shares") into shares of Common Stock. The Preferred Shares were convertible into Shares at the option of the holder, at any time, at a conversion price equal to $0.20 per share. As a result, the Preferred Shares converted into 28,925,000 shares of Common Stock. F1 · kind: On August 6, 2020 Eastern Capital Limited provided notice to the Issuer with effect on August 7, 2020 to convert the shares of Series B Preferred Stock ("Preferred Shares") into shares of Common Stock. The Preferred Shares were convertible into Shares at the option of the holder, at any time, at a conversion price equal to $0.20 per share. As a result, the Preferred Shares converted into 28,925,000 shares of Common Stock. F1 · price: On August 6, 2020 Eastern Capital Limited provided notice to the Issuer with effect on August 7, 2020 to convert the shares of Series B Preferred Stock ("Preferred Shares") into shares of Common Stock. The Preferred Shares were convertible into Shares at the option of the holder, at any time, at a conversion price equal to $0.20 per share. As a result, the Preferred Shares converted into 28,925,000 shares of Common Stock. F1 · derivative.exercise_date: On August 6, 2020 Eastern Capital Limited provided notice to the Issuer with effect on August 7, 2020 to convert the shares of Series B Preferred Stock ("Preferred Shares") into shares of Common Stock. The Preferred Shares were convertible into Shares at the option of the holder, at any time, at a conversion price equal to $0.20 per share. As a result, the Preferred Shares converted into 28,925,000 shares of Common Stock. F1 · derivative.expiration_date: On August 6, 2020 Eastern Capital Limited provided notice to the Issuer with effect on August 7, 2020 to convert the shares of Series B Preferred Stock ("Preferred Shares") into shares of Common Stock. The Preferred Shares were convertible into Shares at the option of the holder, at any time, at a conversion price equal to $0.20 per share. As a result, the Preferred Shares converted into 28,925,000 shares of Common Stock. Read SEC document
August 07, 2020 Filed Aug 11, 2020 17:08 UTC	iBio, Inc. IBIO · Entity 6906	SaleCommon Stock	1,355,604	$3.83	$5,185,591.98	Disclosure SEC source: 0001408408-20-000047 · ownership.xml · nonDerivative · entry 2 Eastern Capital LTD · CIK 0001408408 · 10% owner Portfolio Services Ltd. · CIK 0001488856 · 10% owner DART KENNETH BRYAN · CIK 0001331271 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,758,993 F2 · security: The Price reported in Column 4 is a weighted average price. This transaction was executed in multiple trades at prices ranging from $3.62 to $4.08. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff, the Issuer or a security holder of the Issuer upon request. F2 · price: The Price reported in Column 4 is a weighted average price. This transaction was executed in multiple trades at prices ranging from $3.62 to $4.08. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff, the Issuer or a security holder of the Issuer upon request. Read SEC document
August 07, 2020 Filed Aug 11, 2020 17:08 UTC	iBio, Inc. IBIO · Entity 6906	ConversionCommon Stock	28,925,000	$0.20	$5,785,000.00	Disclosure SEC source: 0001408408-20-000047 · ownership.xml · nonDerivative · entry 1 Eastern Capital LTD · CIK 0001408408 · 10% owner Portfolio Services Ltd. · CIK 0001488856 · 10% owner DART KENNETH BRYAN · CIK 0001331271 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,114,597 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: On August 6, 2020 Eastern Capital Limited provided notice to the Issuer with effect on August 7, 2020 to convert the shares of Series B Preferred Stock ("Preferred Shares") into shares of Common Stock. The Preferred Shares were convertible into Shares at the option of the holder, at any time, at a conversion price equal to $0.20 per share. As a result, the Preferred Shares converted into 28,925,000 shares of Common Stock. F1 · kind: On August 6, 2020 Eastern Capital Limited provided notice to the Issuer with effect on August 7, 2020 to convert the shares of Series B Preferred Stock ("Preferred Shares") into shares of Common Stock. The Preferred Shares were convertible into Shares at the option of the holder, at any time, at a conversion price equal to $0.20 per share. As a result, the Preferred Shares converted into 28,925,000 shares of Common Stock. F1 · price: On August 6, 2020 Eastern Capital Limited provided notice to the Issuer with effect on August 7, 2020 to convert the shares of Series B Preferred Stock ("Preferred Shares") into shares of Common Stock. The Preferred Shares were convertible into Shares at the option of the holder, at any time, at a conversion price equal to $0.20 per share. As a result, the Preferred Shares converted into 28,925,000 shares of Common Stock. Read SEC document
August 06, 2020 Filed Aug 6, 2020 17:33 UTC	iBio, Inc. IBIO · Entity 6906	SaleCommon Stock	2,768,137	$4.18	$11,570,535.85	Disclosure SEC source: 0001408408-20-000039 · ownership.xml · nonDerivative · entry 3 Eastern Capital LTD · CIK 0001408408 · 10% owner Portfolio Services Ltd. · CIK 0001488856 · 10% owner DART KENNETH BRYAN · CIK 0001331271 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,114,597 F3 · security: The Price reported in Column 4 is a weighted average price. This transaction was executed in multiple trades at prices ranging from $4.05 to $4.52. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff, the Issuer or a security holder of the Issuer upon request. F3 · price: The Price reported in Column 4 is a weighted average price. This transaction was executed in multiple trades at prices ranging from $4.05 to $4.52. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff, the Issuer or a security holder of the Issuer upon request. Read SEC document
August 05, 2020 Filed Aug 6, 2020 17:33 UTC	iBio, Inc. IBIO · Entity 6906	SaleCommon Stock	900,000	$4.46	$4,013,550.00	Disclosure SEC source: 0001408408-20-000039 · ownership.xml · nonDerivative · entry 2 Eastern Capital LTD · CIK 0001408408 · 10% owner Portfolio Services Ltd. · CIK 0001488856 · 10% owner DART KENNETH BRYAN · CIK 0001331271 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,882,734 F2 · security: The Price reported in Column 4 is a weighted average price. This transaction was executed in multiple trades at prices ranging from $4.36 to $4.73. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff, the Issuer or a security holder of the Issuer upon request. F2 · price: The Price reported in Column 4 is a weighted average price. This transaction was executed in multiple trades at prices ranging from $4.36 to $4.73. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff, the Issuer or a security holder of the Issuer upon request. Read SEC document
August 04, 2020 Filed Aug 6, 2020 17:33 UTC	iBio, Inc. IBIO · Entity 6906	SaleCommon Stock	600,000	$4.39	$2,636,640.00	Disclosure SEC source: 0001408408-20-000039 · ownership.xml · nonDerivative · entry 1 Eastern Capital LTD · CIK 0001408408 · 10% owner Portfolio Services Ltd. · CIK 0001488856 · 10% owner DART KENNETH BRYAN · CIK 0001331271 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,782,734 F1 · security: The Price reported in Column 4 is a weighted average price. This transaction was executed in multiple trades at prices ranging from $4.31 to $4.47. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff, the Issuer or a security holder of the Issuer upon request. F1 · price: The Price reported in Column 4 is a weighted average price. This transaction was executed in multiple trades at prices ranging from $4.31 to $4.47. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff, the Issuer or a security holder of the Issuer upon request. Read SEC document
June 16, 2020 Filed Jun 19, 2020 11:49 UTC	Marker Therapeutics, Inc. MRKR · Entity 7609	OtherSeries E-1 Warrant · Derivative	416,667	Not disclosed Strike: $15.00	Not disclosed	Disclosure SEC source: 0001408408-20-000029 · ownership.xml · derivative · entry 1 Eastern Capital LTD · CIK 0001408408 · 10% owner Portfolio Services Ltd. · CIK 0001488856 · 10% owner DART KENNETH BRYAN · CIK 0001331271 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 0 shares Expires 2020-06-16 F1 · security: The Series E-1 Warrant to purchase 416,667 shares of Common Stock of the Issuer at the exercise price of $15.00 per share with an expiration date of June 16, 2020, was not exercised by the Reporting Persons before such expiration. F1 · date: The Series E-1 Warrant to purchase 416,667 shares of Common Stock of the Issuer at the exercise price of $15.00 per share with an expiration date of June 16, 2020, was not exercised by the Reporting Persons before such expiration. F1 · shares: The Series E-1 Warrant to purchase 416,667 shares of Common Stock of the Issuer at the exercise price of $15.00 per share with an expiration date of June 16, 2020, was not exercised by the Reporting Persons before such expiration. F1 · price: The Series E-1 Warrant to purchase 416,667 shares of Common Stock of the Issuer at the exercise price of $15.00 per share with an expiration date of June 16, 2020, was not exercised by the Reporting Persons before such expiration. F1 · derivative.expiration_date: The Series E-1 Warrant to purchase 416,667 shares of Common Stock of the Issuer at the exercise price of $15.00 per share with an expiration date of June 16, 2020, was not exercised by the Reporting Persons before such expiration. F1 · derivative.underlying: The Series E-1 Warrant to purchase 416,667 shares of Common Stock of the Issuer at the exercise price of $15.00 per share with an expiration date of June 16, 2020, was not exercised by the Reporting Persons before such expiration. F1 · derivative.underlying_shares: The Series E-1 Warrant to purchase 416,667 shares of Common Stock of the Issuer at the exercise price of $15.00 per share with an expiration date of June 16, 2020, was not exercised by the Reporting Persons before such expiration. Read SEC document
February 18, 2020 Filed Feb 20, 2020 21:50 UTC	Marker Therapeutics, Inc. MRKR · Entity 7609	OtherSeries A-1 Warrant · Derivative	416,667	Not disclosed Strike: $1.20	Not disclosed	Disclosure SEC source: 0001408408-20-000011 · ownership.xml · derivative · entry 2 Eastern Capital LTD · CIK 0001408408 · 10% owner Portfolio Services Ltd. · CIK 0001488856 · 10% owner DART KENNETH BRYAN · CIK 0001331271 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 416,667 shares Expires 2020-03-09 F1 · price: On February 18, 2020, Eastern Capital Limited exercised the Series A-1 Warrant with respect to 416,667 Warrant Shares at an exercise price of $1.20 per share and acquired an additional 416,667 shares of Common Stock. Read SEC document
February 18, 2020 Filed Feb 20, 2020 21:50 UTC	Marker Therapeutics, Inc. MRKR · Entity 7609	OtherCommon Stock	416,667	$1.20	$500,000.40	Disclosure SEC source: 0001408408-20-000011 · ownership.xml · nonDerivative · entry 1 Eastern Capital LTD · CIK 0001408408 · 10% owner Portfolio Services Ltd. · CIK 0001488856 · 10% owner DART KENNETH BRYAN · CIK 0001331271 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,050,001 Read SEC document
July 12, 2018 Filed Jul 13, 2018 16:06 UTC	iBio, Inc. IBIO · Entity 6906	PurchaseCommon Shares	2,200,000	$0.90	$1,980,000.00	Disclosure SEC source: 0001408408-18-000018 · ecl_ibioform407112018.xml · nonDerivative · entry 1 Eastern Capital LTD · CIK 0001408408 · 10% owner Portfolio Services Ltd. · CIK 0001488856 · 10% owner DART KENNETH BRYAN · CIK 0001331271 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,457,734 F1 · security: Eastern Capital Limited acquired 2,200,000 shares of common stock of the Issuer at a price of $0.90 per share as part of an underwritten public offering. Read SEC document
June 26, 2018 Filed Jun 28, 2018 18:03 UTC	iBio, Inc. IBIO · Entity 6906	PurchaseSeries B Preferred Shares · Derivative	5,785	$1,000.00	$5,785,000.00	Disclosure SEC source: 0001408408-18-000014 · ecl_ibioform406282018.xml · derivative · entry 2 Eastern Capital LTD · CIK 0001408408 · 10% owner Portfolio Services Ltd. · CIK 0001488856 · 10% owner DART KENNETH BRYAN · CIK 0001331271 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,785 Underlying: Common Stock · 6,427,778 shares Expires not disclosed F2 · security: The Series B Preferred Shares is convertible into Shares at the option of Eastern Capital Limited, at any time, at a conversion price equal to the public offering price of the Shares, and are subject to a limit of exercise to the extent (and only to the extent) that Eastern Capital Limited or any of its affiliates would beneficially own in excess of 48% of the Shares after giving effect to such exercise. F2 · derivative.exercise_price: The Series B Preferred Shares is convertible into Shares at the option of Eastern Capital Limited, at any time, at a conversion price equal to the public offering price of the Shares, and are subject to a limit of exercise to the extent (and only to the extent) that Eastern Capital Limited or any of its affiliates would beneficially own in excess of 48% of the Shares after giving effect to such exercise. F1 · shares: Eastern Capital Limited acquired 1,683,334 shares of Common Stock of the Issuer (the "Shares") at a price of $0.90 per share and 5,785 Series B Preferred Shares at an offering price of $1,000 per Series B Preferred Share on June 26, 2018, in an underwritten public offering. F2 · derivative.exercise_date: The Series B Preferred Shares is convertible into Shares at the option of Eastern Capital Limited, at any time, at a conversion price equal to the public offering price of the Shares, and are subject to a limit of exercise to the extent (and only to the extent) that Eastern Capital Limited or any of its affiliates would beneficially own in excess of 48% of the Shares after giving effect to such exercise. F2 · derivative.expiration_date: The Series B Preferred Shares is convertible into Shares at the option of Eastern Capital Limited, at any time, at a conversion price equal to the public offering price of the Shares, and are subject to a limit of exercise to the extent (and only to the extent) that Eastern Capital Limited or any of its affiliates would beneficially own in excess of 48% of the Shares after giving effect to such exercise. Read SEC document
June 26, 2018 Filed Jun 28, 2018 18:03 UTC	iBio, Inc. IBIO · Entity 6906	PurchaseCommon Shares	1,683,334	$0.90	$1,515,000.60	Disclosure SEC source: 0001408408-18-000014 · ecl_ibioform406282018.xml · nonDerivative · entry 1 Eastern Capital LTD · CIK 0001408408 · 10% owner Portfolio Services Ltd. · CIK 0001488856 · 10% owner DART KENNETH BRYAN · CIK 0001331271 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,257,734 F1 · security: Eastern Capital Limited acquired 1,683,334 shares of Common Stock of the Issuer (the "Shares") at a price of $0.90 per share and 5,785 Series B Preferred Shares at an offering price of $1,000 per Series B Preferred Share on June 26, 2018, in an underwritten public offering. Read SEC document
May 14, 2018 Filed May 16, 2018 21:28 UTC	Marker Therapeutics, Inc. TPIV · Entity 7609	PurchaseCommon Stock	1,300,000	$2.40	$3,120,000.00	Disclosure SEC source: 0001408408-18-000007 · ecl_tpivf4052018.xml · nonDerivative · entry 1 Eastern Capital LTD · CIK 0001408408 · 10% owner Portfolio Services Ltd. · CIK 0001488856 · 10% owner DART KENNETH BRYAN · CIK 0001331271 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,300,002 F1 · security: On May 14, 2018, Eastern Capital Limited entered into a Common Stock Purchase Agreement with the Issuer to purchase 1,300,000 shares of common stock at a price per share of $2.40. Read SEC document
November 30, 2017 Filed Dec 4, 2017 17:14 UTC	iBio, Inc. IBIO US · Entity 6906	PurchaseCommon Stock	12,000,000	$0.20	$2,400,000.00	Disclosure SEC source: 0001408408-17-000036 · ecl-ibiof412042017.xml · nonDerivative · entry 1 Eastern Capital LTD · CIK 0001408408 · 10% owner Portfolio Services Ltd. · CIK 0001488856 · 10% owner DART KENNETH BRYAN · CIK 0001331271 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,744,000 Read SEC document
July 19, 2017 Filed Jul 21, 2017 21:37 UTC	Bio Green Med Solution, Inc. CYCC · Entity 8225	PurchaseWarrant · Derivative	1	Not disclosed Strike: $2.00	Not disclosed	Disclosure SEC source: 0001408408-17-000016 · cyccform4_07192017.xml · derivative · entry 2 Eastern Capital LTD · CIK 0001408408 · 10% owner Portfolio Services Ltd. · CIK 0001488856 · 10% owner DART KENNETH BRYAN · CIK 0001331271 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1 Underlying: Common Stock · 850,000 shares Expires not disclosed F1 · security: On July 19, 2017 Eastern Capital Limited acquired 850,000 Class A Units. Each Class A Unit consists of one share of the Issuer's common stock and a warrant to purchase one share of the Issuer's common stock which is exercisable as of July 21, 2017 with an exercise price of $2.00 per share and which expires on July 22, 2024. F1 · date: On July 19, 2017 Eastern Capital Limited acquired 850,000 Class A Units. Each Class A Unit consists of one share of the Issuer's common stock and a warrant to purchase one share of the Issuer's common stock which is exercisable as of July 21, 2017 with an exercise price of $2.00 per share and which expires on July 22, 2024. F1 · price: On July 19, 2017 Eastern Capital Limited acquired 850,000 Class A Units. Each Class A Unit consists of one share of the Issuer's common stock and a warrant to purchase one share of the Issuer's common stock which is exercisable as of July 21, 2017 with an exercise price of $2.00 per share and which expires on July 22, 2024. F1 · derivative.exercise_date: On July 19, 2017 Eastern Capital Limited acquired 850,000 Class A Units. Each Class A Unit consists of one share of the Issuer's common stock and a warrant to purchase one share of the Issuer's common stock which is exercisable as of July 21, 2017 with an exercise price of $2.00 per share and which expires on July 22, 2024. F1 · derivative.expiration_date: On July 19, 2017 Eastern Capital Limited acquired 850,000 Class A Units. Each Class A Unit consists of one share of the Issuer's common stock and a warrant to purchase one share of the Issuer's common stock which is exercisable as of July 21, 2017 with an exercise price of $2.00 per share and which expires on July 22, 2024. Read SEC document
July 19, 2017 Filed Jul 21, 2017 21:37 UTC	Bio Green Med Solution, Inc. CYCC · Entity 8225	PurchaseCommon Stock	850,000	$2.00	$1,700,000.00	Disclosure SEC source: 0001408408-17-000016 · cyccform4_07192017.xml · nonDerivative · entry 1 Eastern Capital LTD · CIK 0001408408 · 10% owner Portfolio Services Ltd. · CIK 0001488856 · 10% owner DART KENNETH BRYAN · CIK 0001331271 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,167,261 F1 · security: On July 19, 2017 Eastern Capital Limited acquired 850,000 Class A Units. Each Class A Unit consists of one share of the Issuer's common stock and a warrant to purchase one share of the Issuer's common stock which is exercisable as of July 21, 2017 with an exercise price of $2.00 per share and which expires on July 22, 2024. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.